Mesoblast (MEOBF) Liabilities and Shareholders Equity (2017 - 2025)

Mesoblast (MEOBF) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $784.7 million as the latest value for Q2 2025.

  • Quarterly Liabilities and Shareholders Equity rose 17.27% to $784.7 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 billion through Jun 2025, up 1.46% year-over-year, with the annual reading at $784.7 million for FY2025, 17.27% up from the prior year.
  • Liabilities and Shareholders Equity hit $784.7 million in Q2 2025 for Mesoblast, up from $669.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $784.7 million in Q2 2025 to a low of $662.1 million in Q2 2022.
  • Historically, Liabilities and Shareholders Equity has averaged $706.0 million across 5 years, with a median of $669.4 million in 2023.
  • Biggest five-year swings in Liabilities and Shareholders Equity: fell 11.09% in 2022 and later rose 17.27% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $744.7 million in 2021, then fell by 11.09% to $662.1 million in 2022, then grew by 1.1% to $669.4 million in 2023, then fell by 0.04% to $669.2 million in 2024, then rose by 17.27% to $784.7 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for MEOBF at $784.7 million in Q2 2025, $669.2 million in Q2 2024, and $669.4 million in Q2 2023.